EVAN M HERSH, MD
Osteopathic Medicine at Campbell Ave, Tucson, AZ

6709858, Mar 23, 2004

Nov 3, 1998

09/185243

Tom Tsang - Tucson AZ
Eugene W. Gerner - Tucson AZ
David T. Harris - Tucson AZ
Evan Hersh - Tucson AZ

The Arizona Board of Regents on behalf of The University of Arizona - Tucson AZ

C12N 1585

4353201, 435 691, 435455, 435456, 435458, 424 932, 514 44

Methods and compositions are provided for transgene expression in target cells. Expression constructs using an inducible amplification system to drive expression of a therapeutic gene or other gene of interest in mammalian host cells are provided, as well as methods therefor. Inducible expression of the transgenes at high levels under physiologic conditions results from induction by hyperthermic conditions relative to the basal temperature of the host cells.

2007004, Mar 1, 2007

Aug 29, 2006

11/512998

Evan Hersh - Tucson AZ, US
Kathryn Grenier - Tucson AZ, US

AmpliMed Corporation - Tucson AZ

A61K 31/715, A61K 31/7072, A61K 31/337

424078300, 514054000, 514049000, 514449000

Methods of treating imexon-induced constipation in patients in conjunction with their participation in a cancer treatment regimen are disclosed herein. Embodiments of the invention include the treatment of imexon-induced constipation arising from the administration of imexon alone or in combination with other chemotherapeutic agents. Also disclosed are pharmaceutical compositions and pharmaceutical kits comprising a therapeutically effective amount of imexon and an amount of a laxative effective in treating imexon-induced constipation. Embodiments of the present invention include prophylactic anticonstipation regimens comprising one or more laxatives that may be prescribed and/or administered prior to or during the course of treatment of the patient with imexon.

5695927, Dec 9, 1997

Jul 1, 1994

8/270214

Yasuhiko Masuho - Tokyo, JP
Toru Sugano - Tokyo, JP
Yoh-ichi Matsumoto - Kichijohjikita-machi, JP
Takashi Kawamura - Tokyo, JP
Evan Hersh - Tucson AZ
Eskild Petersen - Tucson AZ
Douglas Lake - Tucson AZ

The University of Arizona, Department of Internal Medicine, Section of
Hematology and Oncology - Tucson AZ
Teijin Limited - Osaka

C12Q 170

435 5

Human monoclonal antibodies which belong to the IgG1 subclass and are specific for HIV are described. The monoclonal antibodies have potential for use in the diagnosis, prevention and therapy of HIV infection.

2007021, Sep 13, 2007

Mar 1, 2007

11/681120

Robert Dorr - Tucson AZ, US
Evan Hersh - Tucson AZ, US
David Alberts - Tucson AZ, US

AmpliMed Corporation - Tucson AZ

A61K 31/473

514288000

Compositions and methods for treating multiple sclerosis are disclosed herein. Embodiments of the present invention include methods of treating a multiple sclerosis patient via the administration of a therapeutically effective amount of a composition comprising a compound of the formula: wherein,

4978654, Dec 18, 1990

Jan 12, 1987

7/002455

Victor Fainstein - Houston TX
Evan M. Hersh - Tucson AZ
Roy L. Hopfer - Houston TX
Rudolph L. Juliano - Houston TX
Kapil Mehta - Houston TX
Reeta Mehta - Houston TX

Board of Regents, The University of Texas System - Austin TX

A61K 3170, A61K 31685

514 31

A method is disclosed for treatment of disseminated fungal infection in a mammal comprising the administration of a fungicidally effective amount of Amphotericin B encapsulated in a substantially sterol-free liposome to the infected mammal. Also provided is an agent for treatment of disseminated fungal infection in a mammal comprising Amphotericin B encapsulated in a liposome which consists essentially of lipids other than sterols.

5783670, Jul 21, 1998

Jun 7, 1995

8/487529

Yasuhiko Masuho - Tokyo, JP
Toru Sugano - Tokyo, JP
Yoh-ichi Matsumoto - Tokyo, JP
Takashi Kawamura - Tokyo, JP
Evan Hersh - Tucson AZ
Eskild Petersen - Tucson AZ
Douglas Lake - Tucson AZ

The University of Arizona, Department of Internal Medicine, Section of
Hematology and Oncology - Tucson AZ
Teijin Limited - Osaka

C07K 1610, A61K 3942

53038815

Human monoclonal antibodies which belong to the IgGl subclass and are specific for HIV are described. The monoclonal antibodies have potential for use in the diagnosis, prevention and therapy of HIV infection.